Core Viewpoint - The article highlights the significant growth and competitive advantages of Jinhe Biological, particularly in the veterinary pharmaceutical sector, driven by rising demand and pricing power in the livestock industry, as well as the burgeoning pet economy in China [1][5]. Group 1: Industry Trends - In the U.S., beef prices have reached historical highs, with ground beef prices increasing by 12% year-on-year in June. In China, the number of beef cattle decreased by 2.33% month-on-month in May, while calf prices surged by 26.37% year-on-year as of July 11 [1]. - The upward trend in calf prices and the decline in beef cattle inventory are expected to support beef prices in the latter half of 2025 and into 2026, indicating a sustained cycle of profitability in the beef industry [3]. Group 2: Company Performance - Jinhe Biological, a leader in the veterinary pharmaceutical market with a 50% global market share in oxytetracycline, has experienced rapid growth in performance this year, with a stock price increase of over 90% by April 10 [1][2]. - The company's net profit attributable to shareholders for the first half of 2025 increased by 51.52% year-on-year, reaching 138 million yuan, driven by increased sales of oxytetracycline and reduced raw material costs [2]. Group 3: Business Strategy and Growth Drivers - The company has established a dual-channel strategy in the pet health sector, with a focus on both imported and domestic brands, and has launched an AI-powered pet care app [4]. - The pet industry in China is projected to grow from 170.8 billion yuan in 2018 to 300.2 billion yuan by 2024, with a compound annual growth rate of 9.86% [4]. - Jinhe Biological's vaccine business is expected to see significant growth, particularly with the brucellosis vaccine, which has a market potential of around 4 billion yuan and could grow to 20 billion yuan due to increased demand and pricing [21]. Group 4: Competitive Advantages - The company benefits from scale advantages that drive cost reductions and efficiency improvements, with plans for a new factory expected to enhance profitability and reduce production costs [12]. - Jinhe Biological has established strong technical barriers and innovation capabilities, collaborating with research institutions to improve product quality and reduce impurities in its products [13][14]. - The company has a diversified business model that includes environmental protection and agricultural product processing, which contribute to stable performance [15]. Group 5: Future Outlook - The company aims to leverage its dual-drivers of pharmaceutical and vaccine segments to transition from a cyclical to a growth-oriented enterprise, indicating long-term investment value [28].

Core Viewpoint - The company has proposed a cash dividend distribution plan for the first half of 2025, reflecting its profitability and commitment to shareholder returns [1][2][3]. Profit Distribution Plan - As of June 30, 2025, the company reported a net profit attributable to shareholders of 117,181,542.91 yuan, resulting in a total distributable profit of 372,964,159.44 yuan after accounting for previous distributions [1]. - The proposed cash dividend is 1.00 yuan per 10 shares, totaling 20,157,895.70 yuan, which represents 17.20% of the net profit for the first half of 2025 [2][3]. - The total number of shares for the dividend calculation is based on 201,578,957 shares after excluding treasury shares [2]. Approval Process and Legitimacy - The dividend proposal has been authorized by the 2024 annual general meeting, allowing the board to decide on the mid-year dividend based on actual conditions [2]. - The distribution plan complies with relevant regulations and the company's articles of association, ensuring its legality and reasonableness [3]. Additional Information - The company has taken measures to prevent insider trading and ensure confidentiality regarding the dividend proposal [3]. - The proposed distribution is designed to balance shareholder returns with the company's operational needs and long-term development [3].

Investment Rating - The report maintains a "Recommended" rating for the agricultural, forestry, animal husbandry, and fishery industry [1][8]. Core Viewpoints - The report highlights a long-term revaluation opportunity for the pig industry, indicating that while pig prices are experiencing fluctuations, there is still downward pressure. The industry is expected to transition towards a self-regulatory and stable phase, benefiting leading companies such as Wens Foodstuffs, Muyuan Foods, and Juxing Agriculture [4][14]. - The poultry sector is currently facing low prices, but there are signs of marginal improvement in the cycle, with recommendations for companies like Shennong Development and Lihua Stock [5][24]. - The animal health sector is anticipated to see performance recovery and investment opportunities in pet medical services, with a focus on companies like Kexin Biological and Ruipuhua [6][34]. - The planting sector is experiencing a decline in the pig-to-grain price ratio, with ongoing commercialization of genetically modified seeds benefiting early adopters [7][37]. - The feed sector is witnessing price fluctuations, with recommendations for Haida Group and attention to He Feng Stock [7][42]. - The pet economy is thriving, with domestic brands gaining strength, and the report recommends companies in the pet food sector such as Guibao Pet and Zhongchong Stock [7][51]. Summary by Sections Pig Industry - The average price of pigs is currently around 14.08 yuan/kg, with fluctuations noted [14]. - The number of breeding sows has increased slightly, indicating a stable supply [14]. - Key recommendations include Wens Foodstuffs, Muyuan Foods, and Juxing Agriculture, with a suggestion to pay attention to Dekang Agriculture [4][14]. Poultry Industry - The price of white feather chicken is low, with a focus on potential marginal improvements in the cycle [5][23]. - The report notes a significant update in the breeding stock, with a mix of imported and self-bred varieties [5][24]. - Recommended companies include Shennong Development and Lihua Stock [5][24]. Animal Health - The report anticipates continued recovery in animal health companies' performance, supported by stable profits in the pig farming sector [6][34]. - The approval of mRNA vaccines for veterinary use marks a significant technological advancement [6][34]. - Recommended companies include Kexin Biological and Ruipuhua, with additional attention to Huisheng Biological and Jinhai Biological [6][34]. Planting Sector - The pig-to-grain price ratio has decreased, with ongoing commercialization of genetically modified seeds [7][37]. - Recommendations include Suqian Agricultural Development and Longping High-Tech [7][37]. Feed Sector - Feed prices are experiencing fluctuations, with specific prices noted for different types of feed [7][42]. - The report suggests that the feed industry is likely to see increased concentration, recommending Haida Group and monitoring He Feng Stock [7][42]. Pet Industry - The pet market is growing, with a significant increase in consumption and brand development [7][51]. - Recommendations include Guibao Pet, Zhongchong Stock, and Peidi Stock in the pet food sector, as well as Ruipuhua in the pet medical sector [7][51].

Investment Rating - The report maintains a "Buy" rating for the agricultural, forestry, animal husbandry, and fishery sector, indicating an expected investment return exceeding 15% over the next 6-12 months [5]. Core Insights - The report highlights a strong rebound in meat and poultry prices due to increased stocking and the arrival of the consumption peak season [1][2]. - The pig price has shown a week-on-week increase of 1.27%, with the average price reaching 14.33 yuan/kg as of August 1 [23]. - The white feathered chicken price rose by 1.94% to 6.83 yuan/kg, while chick prices surged by 33.16% to 2.57 yuan/bird, driven by limited market supply and increased stocking enthusiasm among farmers [2][35]. - Corn and wheat prices have decreased slightly, while soybean meal prices have increased, indicating mixed trends in feed costs [3][50]. Summary by Sections 1. Market Overview - The agricultural sector underperformed against the broader market, with the agricultural index declining by 2.97% [14]. - The animal husbandry segment saw a significant drop, particularly in pig farming, which fell by 4.63% [14]. 2. Key Data Tracking - Pig prices increased to 14.33 yuan/kg, while the average weight of pigs at slaughter was 127.98 kg, reflecting a slight decrease [22][23]. - The white feathered chicken price reached 6.83 yuan/kg, and chick prices rose significantly, indicating a recovery in the poultry market [35][21]. - Yellow chicken prices improved due to seasonal demand, with medium-speed chicken prices increasing by 8.33% to 5.46 yuan/jin [45]. 3. Investment Recommendations - The report recommends focusing on the pig farming sector, anticipating a favorable supply-demand balance in August, with key companies to watch including Muyuan Foods, Wens Foodstuff Group, and Juxing Agriculture [4][71]. - For the feed and veterinary sectors, companies like Haida Group and Reap Bio are highlighted due to rising demand from increased pig stocks [4][71]. - In the planting chain, companies such as Suqian Agricultural Development and Beidahuang are recommended as grain prices are expected to rise [4][71]. - The pet food sector is also noted for growth potential, with companies like Guibao Pet and Zhongchong Co. being highlighted [4][74].

Core Viewpoint - The company Jinhe Biological has shown significant growth in its operating performance, with a notable increase in revenue and net profit in the first half of 2025, driven primarily by its veterinary pharmaceutical segment [1][2]. Financial Performance - In the first half of 2025, the company achieved revenue of 1.39 billion yuan, representing a year-on-year growth of 30.45% [1][2]. - The net profit for the same period reached 138 million yuan, marking a year-on-year increase of 51.52% [1][2]. - The gross profit margin improved to 34.55%, up 1.25 percentage points from the previous year, due to effective cost control [2]. Business Segments - The veterinary pharmaceutical segment is the core driver of growth, with revenue from this segment reaching 860 million yuan in the first half of 2025, a substantial increase of 72.15% year-on-year, accounting for 61.83% of total revenue [1][2]. - The company has established a diversified product matrix in the veterinary pharmaceutical field, focusing on the core product of premixed gentamicin [3][4]. Market Expansion - Jinhe Biological's overseas business generated revenue of 588 million yuan in the first half of 2025, reflecting a year-on-year growth of 65.5% and accounting for 42.3% of total revenue [3]. - The company has successfully penetrated over 10 countries and regions, with the United States being the largest overseas market, representing approximately two-thirds of its exports [3]. Research and Development - The company has invested a total of 529 million yuan in research and development over the past five and a half years, with a significant increase in R&D spending in 2025 [4][5]. - Jinhe Biological has established two major research centers for animal vaccines and has developed a rich product portfolio, including 16 vaccine products covering various animal types [5].

Core Viewpoint - Jinhe Biology demonstrated strong financial performance in the first half of 2025, with significant revenue and profit growth, particularly in the veterinary chemical drug sector [2][11]. Financial Overview - Total revenue reached 1.39 billion yuan, a year-on-year increase of 30.45% [2]. - Net profit attributable to shareholders was 138 million yuan, up 51.52% year-on-year [2]. - The second quarter saw total revenue of 765 million yuan, a 40.05% increase, and net profit of 86.8 million yuan, growing by 89.2% [2]. Profitability - The company's gross margin improved to 34.55%, an increase of 3.76% year-on-year [3]. - Net profit margin rose to 9.92%, up 16.73% year-on-year, indicating effective cost control and enhanced product value [3]. Costs and Expenses - Total operating expenses amounted to 279 million yuan, accounting for 20.03% of revenue, an increase of 2.32% year-on-year [4]. - Management expenses grew by 36.2%, primarily due to salary increases, depreciation from completed projects, and increased stock incentive costs [4]. - Financial expenses rose by 46.74%, attributed to interest expenses from completed projects and reduced foreign exchange gains in the previous year [4]. Cash Flow and Debt Situation - Cash and cash equivalents decreased to 625 million yuan, down 5.21% year-on-year [5]. - Operating cash flow per share was 0.17 yuan, a decline of 20.08% [5]. - Net cash flow from financing activities dropped by 95.88%, and net increase in cash and cash equivalents fell by 89.9% [5]. - Interest-bearing liabilities increased to 2.528 billion yuan, up 0.72% year-on-year, with an interest-bearing asset-liability ratio of 41.41% [5]. Accounts Receivable - Accounts receivable stood at 590 million yuan, a year-on-year increase of 22.22%, with a ratio to profit of 589.11%, indicating a need to monitor collection [6]. Main Business Analysis - The veterinary chemical drug segment generated 860 million yuan, accounting for 61.83% of total revenue, with a gross margin of 38.13% [7]. - Revenue from starch and related products was 275 million yuan, making up 19.76% of total revenue, with a gross margin of 11.15% [7]. - Veterinary vaccine revenue reached 155 million yuan, representing 11.12% of total revenue, with a gross margin of 54.87% [7]. - Environmental services contributed 69.13 million yuan, accounting for 4.97% of total revenue, with a gross margin of 44.25% [7]. Regional Distribution - Domestic sales revenue was 802 million yuan, accounting for 57.67% of total revenue, with a gross margin of 26.59% [8]. - International sales revenue reached 588 million yuan, making up 42.33% of total revenue, with a gross margin of 45.40% [8]. Development Strategy - The company focuses on its core animal health business, with a dual-driven model of veterinary pharmaceuticals and vaccines, supported by environmental and agricultural processing sectors [9]. - The completion of the sixth phase project added 60,000 tons of production capacity for key products, enhancing competitiveness through cost reduction and improved fermentation indices [9]. - The veterinary vaccine business has rapidly established a comprehensive industry layout through self-built and acquired production bases and R&D centers [9].

Investment Rating - The investment rating for the company is "Buy" [1][6]. Core Views - The company reported a significant increase in revenue and net profit for the first half of 2025, with revenue reaching 1.39 billion yuan, up 30.45% year-on-year, and net profit of 138 million yuan, up 51.52% year-on-year [2]. - The veterinary pharmaceutical segment showed remarkable performance, with revenue of 860 million yuan, a year-on-year increase of 72.15%, accounting for 61.83% of total revenue [3]. - The vaccine segment maintained a stable foundation despite a slight revenue decline, with income of 155 million yuan, down 0.92% year-on-year, representing 11.12% of total revenue [4]. - The company is well-positioned to benefit from domestic and international market demand growth, cost optimization, and price increases, particularly in the veterinary pharmaceutical sector [5]. Summary by Sections Financial Performance - The company achieved a total revenue of 2.371 billion yuan in 2024, projected to grow to 2.835 billion yuan in 2025, and further to 3.030 billion yuan in 2026 [10]. - The net profit is expected to rise from 100 million yuan in 2024 to 197 million yuan in 2025, and 326 million yuan in 2026 [10]. - The gross margin is projected to be 33.5% in 2024, decreasing slightly to 31.9% in 2025, and then increasing to 36.4% in 2026 [10]. Business Segments - The veterinary pharmaceutical segment's gross margin was 38.13%, despite a slight year-on-year decrease due to lower-margin product sales [3]. - The vaccine segment's gross margin was 54.87%, down 5.50 percentage points year-on-year, influenced by increased market competition and customer cost-cutting [4]. - The company is expanding its product pipeline with over 20 products in research and registration, including new vaccines for various diseases [4]. Future Outlook - The company is expected to maintain a dual-driven strategy with its pharmaceutical and vaccine segments, supported by ongoing research and development efforts [5]. - The projected earnings per share (EPS) are expected to increase from 0.13 yuan in 2024 to 0.26 yuan in 2025, and 0.42 yuan in 2026 [10].

Investment Rating - The industry is rated as "stronger than the market," indicating an expected increase in the industry index relative to the market by over 10% in the next six months [28]. Core Insights - As of July 28, 2025, the agricultural, forestry, animal husbandry, and fishery sector has shown a positive trend, with 54 out of 113 listed companies in the sector releasing performance forecasts for the first half of 2025, resulting in a disclosure rate of 48%, the highest among eight major consumer industries [2][9][10]. - The sector's pre-profit rate stands at 69%, with 37 companies expected to be profitable, marking a significant increase in the proportion of companies forecasting profit and growth compared to the previous year [2][10]. - The proportion of companies expecting profit growth has surged from 10% to 28%, while the percentage of companies reporting losses has decreased from 41% to 31%, with 24% of companies turning losses into profits [2][10]. Summary by Sections Performance Overview - The agricultural, forestry, animal husbandry, and fishery sector has a pre-profit rate of 69%, ranking second among consumer industries, with a notable increase in the number of companies forecasting profit [2][10]. - The animal husbandry and animal health sectors have shown particularly strong performance, with a pre-profit rate of 80%, while other sectors like agricultural products processing and fishery also performed well with pre-profit rates of 75% [3][14][15]. Subsector Analysis - The planting sector has underperformed compared to last year, with the proportion of companies forecasting profit growth dropping from 33% to 29%, and 14% of companies reporting first-time losses [3][15]. - The feed sector has shown stability, with 45% of companies turning losses into profits, while the agricultural products processing sector has seen a mixed performance, with a profit growth forecast increasing from 20% to 50% despite 13% of companies reporting continuous losses [3][15]. - The animal husbandry sector has seen a significant reduction in the proportion of companies continuing to report losses, dropping from 33% to 7%, and two-thirds of companies in the animal health sector expect substantial profit growth [3][15].

Group 1 - The World Health Organization warns that the Chikungunya virus is spreading globally, with 119 countries reporting cases and approximately 5.5 million people at risk of infection [1] - In Foshan, Guangdong Province, over 4,000 confirmed cases of Chikungunya have been reported, with Shunde District accounting for 3,627 cases, all of which are mild [1] Group 2 - Domestic animal health mRNA vaccines are entering a clinical boom, with recent approvals for clinical trials of mRNA vaccines for pig diarrhea and cat infectious peritonitis [2] - The rapid approval of mRNA vaccines reflects an accelerating trend in the application of mRNA technology in animal health, although the high development barriers pose risks for investors [2] Group 3 - Huaxi Bio issued a statement addressing false information circulating online, emphasizing the malicious nature of the claims and the background of the individual responsible for the misinformation [3] - The company's swift response highlights its commitment to managing reputation risks, especially in the sensitive beauty and medical aesthetics industry [3] Group 4 - Guangsheng Tang announced the successful enrollment of the first subject in the Phase III clinical trial for its innovative hepatitis B treatment, GST-HG141, marking a significant milestone in its development [4] - GST-HG141 is a novel hepatitis B core protein/capsid regulator and is the first of its kind with global intellectual property rights held by Guangsheng Tang [4]

截至2025年7月25日收盘，中牧股份（600195）报收于7.88元，较上周的7.89元下跌0.13%。本周，中牧 股份7月25日盘中最高价报8.03元。7月24日盘中最低价报7.75元。中牧股份当前最新总市值80.47亿元， 在动物保健板块市值排名4/11，在两市A股市值排名2113/5148。 本周关注点 公司公告汇总: 中牧股份收到首笔搬迁补偿款人民币贰仟万元整 公司公告汇总 中牧实业股份有限公司（股票代码：600195）于2024年10月29日召开第八届董事会2024年第二十一次临 时会议，审议通过了关于公司拟签订《成都市国有土地上房屋搬迁补偿协议》的议案，同意公司与成都 成华棚户区惠民改造建设有限责任公司签订关于成都市成华区蜀陵路59号的搬迁补偿协议，并授权公司 管理层操作具体事宜。2024年11月13日，双方正式签订了该协议，搬迁补偿款将分阶段支付。2025年7 月23日，公司收到首笔搬迁补偿款人民币贰仟万元整（¥20,000,000.00）。公司将根据《企业会计准 则》对上述款项进行相应会计处理，具体影响以会计师事务所年度审计结果为准。本次搬迁事项符合相 关法律法规和政策文件的规定，涉及的土地 ...